ライフサイエンスコーパス: disease recurrence

1 failure/death during treatment or subsequent disease recurrence).

2 cesses to prevent C. difficile infection and disease recurrence.

3 urveillance could accurately detect clinical disease recurrence.

4 treatment are associated with lower risk of disease recurrence.

5 els and the AR/TRIM24 gene signature predict disease recurrence.

6 and even liver transplantation has a risk of disease recurrence.

7 er to monitor treatment response and risk of disease recurrence.

8 ues in restaging for patients with suspected disease recurrence.

9 ons of resistant leukemia cells that mediate disease recurrence.

10 d GSC differentiation and invasive growth in disease recurrence.

11 ies that can identify recipients at risk for disease recurrence.

12 he optimal strategy to prevent postoperative disease recurrence.

13 rsal, with some individuals suffering severe disease recurrence.

14 -mediated killing of tumor cells and prevent disease recurrence.

15 lone for prevention of postoperative Crohn's disease recurrence.

16 retinal vascularisation without any signs of disease recurrence.

17 stage but is correlated to a higher risk of disease recurrence.

18 ormal in 44 (39.3%) patients; 35 (31.3%) had disease recurrence.

19 stoperative PTH also independently predicted disease recurrence.

20 (but not any pair alone) was associated with disease recurrence.

21 colonic cancer surgery increases the risk of disease recurrence.

22 costs, and is characterized by high rates of disease recurrence.

23 ve intent treatment for earlier detection of disease recurrence.

24 orts have described highly variable rates of disease recurrence.

25 .1-54.7 months), 15 patients (13%) developed disease recurrence.

26 Two hundred twenty-one patients had disease recurrence.

27 tion in this phenotypic transition, modeling disease recurrence.

28 ems to improve overall survival and decrease disease recurrence.

29 ified here is a robust prognostic marker for disease recurrence.

30 g AR alone can result in drug resistance and disease recurrence.

31 clinically quiet eye may point to impending disease recurrence.

32 o eradicate residual cancer cells to prevent disease recurrence.

33 hether urine TERT status was an indicator of disease recurrence.

34 prior to, and following food antigen induced disease recurrence.

35 ared with clinical findings, to detection of disease recurrence.

36 tcomes are unclear but may be related to HCV disease recurrence.

37 and resistant tumors was a common feature of disease recurrence.

38 ns for long-term steroid delivery to prevent disease recurrence.

39 accurately reflect a cell's ability to drive disease recurrence.

40 ing or clinical events prompted suspicion of disease recurrence.

41 ations (25.2%), and 32 patients (14.9%) with disease recurrence.

42 t metastasis and is a candidate predictor of disease recurrence.

43 is significantly reduced by the high rate of disease recurrence.

44 of medications used, drug side effects, and disease recurrence.

45 expression correlated with an early time to disease recurrence.

46 d a possible increased risk of primary renal disease recurrence.

47 or to OCR in direct measures of survival and disease recurrence.

48 y but are associated with increased risk for disease recurrence.

49 igh risk of treatment-related morbidity, and disease recurrence.

50 may be associated with reduction in risk for disease recurrence.

51 ril 2010), 435 patients had died and 376 had disease recurrence.

52 nning of cervical cancer and for identifying disease recurrence.

53 g which frequently changes after therapy and disease recurrence.

54 T) for chronic lymphocytic leukemia (CLL) is disease recurrence.

55 nverse correlation between B cell memory and disease recurrence.

56 gnostic factor for poor overall survival and disease recurrence.

57 in clear predictors of postoperative Crohn's disease recurrence.

58 ugs may occur in cancer patients, leading to disease recurrence.

59 modify the course of the disease and reduce disease recurrence.

60 e, and predict the risk of complications and disease recurrence.

61 rvival of residual MM cells, contributing to disease recurrence.

62 gic malignancies frequently fails because of disease recurrence.

63 ed a good health status, without any sign of disease recurrence.

64 treatment resistance, tumor metastasis, and disease recurrence.

65 over self-renewal capacity and contribute to disease recurrence.

66 with better quality of life and low risk of disease recurrence.

67 Six patients (23%) developed disease recurrence.

68 cancer (LACC), 40% of patients present with disease recurrence.

69 ded with a striking reduction in the time to disease recurrence.

70 increase in macrophages/microglia cells upon disease recurrence.

71 the most predictive features associated with disease recurrence.

72 re reviewed for liver biopsy to evaluate for disease recurrence.

73 g the probability of acquired resistance and disease recurrence.

74 y and inflammation as potential triggers for disease recurrence.

75 biotics is being actively pursued to prevent disease recurrence.

76 ere it can contribute to drug resistance and disease recurrence.

77 iding sustained benefit through reduction in disease recurrence.

78 culosis (TB) disease are at elevated risk of disease recurrence.

79 ncer in patients who are suspected of having disease recurrence?

80 f 4.8 years, a total of 30 patients have had disease recurrence, 11 involving the liver.

81 Patient outcomes were excellent with 2 disease recurrence (3.8%) and all patients ultimately ac

82 LR group, without significant differences in disease recurrence, 3- or 5-year overall survival(OS) an

83 ies was significantly lower in patients with disease recurrence (7.6 % vs 21.3% of biopsies, P = 0.03

84 tumors was an independent predictor of early disease recurrence (adjusted hazard ratio=4.1; 95% confi

85 e of stromal Cav-1 was associated with early disease recurrence, advanced tumor stage, and lymph node

86 ategies that are being developed to overcome disease recurrence after both allo-HSCT and autologous H

87 B-cell lymphoma and used to predict clinical disease recurrence after frontline treatment.

88 tenin synergizes with imatinib (IM) to delay disease recurrence after imatinib discontinuation and to

89 these areas of unmet needs is prevention of disease recurrence after liver transplantation.

90 cant proportion of sarcoidosis patients have disease recurrence after LT and presence of active granu

91 EST expression is negatively correlated with disease recurrence after prostatectomy, invite a deeper

92 positive resection margin is a predictor of disease recurrence after resection of colorectal liver m

93 Disease recurrence after surgery and/or radiation and di

94 Predictors of Crohn's disease recurrence after surgery include cigarette smoki

95 h cells were associated with shorter time to disease recurrence after surgery.

96 after liver transplantation, graft loss from disease recurrence after transplantation is uncommon.

97 Although 30%-50% of these patients suffer disease recurrence after transplantation, with poor long

98 ce a variety of challenges as they cope with disease recurrence and a myriad of normal tissue complic

99 currence Score (RS) assay is used to predict disease recurrence and benefit of chemotherapy in estrog

100 tatectomy is associated with a lower risk of disease recurrence and better prostate cancer specific m

101 The risks of disease recurrence and bone metastasis were also signifi

102 sustained benefits in terms of reduction of disease recurrence and breast cancer mortality.

103 The aim of the current study is to describe disease recurrence and clinical course after LT.

104 EoE necessitates long-term therapy to avoid disease recurrence and complications.

105 Patients were observed until March 2009 for disease recurrence and death.

106 pants was not associated with a reduction of disease recurrence and death.

107 ssion of TSGs strongly correlates with early disease recurrence and decreased overall survival.

108 However, disease recurrence and development of metastatic disease

109 e data sets and is by itself associated with disease recurrence and disease-specific survival.

110 12 rate (85%) including patients with severe disease recurrence and F3-4 cirrhosis.

111 transplantation, there is very high risk of disease recurrence and graft loss.

112 been used for diagnosis and surveillance of disease recurrence and imaging has revolutionised oncolo

113 cancer (CRC) and are associated with reduced disease recurrence and improved outcome after primary tr

114 ding of preoperative parameters that predict disease recurrence and inclusion of concomitant subvalvu

115 elevated, correlating with prolonged time to disease recurrence and inversely correlating with tumor

116 The rates of HCV-related disease recurrence and liver fibrosis progression among

117 conducted to investigate the impact of AL on disease recurrence and long-term survival.

118 he prognostic significance of CTC status for disease recurrence and melanoma-specific survival (MSS).

119 ve also suggested their potential to prevent disease recurrence and metastases.

120 Low levels of SOCS2 correlated strongly with disease recurrence and metastasis in clinical specimens.

121 of Ron receptor activation, correlates with disease recurrence and metastasis in patients.

122 stem cell phenotype, which is implicated in disease recurrence and metastasis.

123 nt tumours correlates with increased risk of disease recurrence and metastatic PCa.

124 iation of diabetes with an increased risk of disease recurrence and mortality in the setting of colon

125 mic p23 expression more accurately predicted disease recurrence and mortality than did stage alone.

126 Risks of disease recurrence and non-RCC death were estimated by u

127 h nuclear STAT5A/B expression predicts early disease recurrence and PCa-specific death in clinical PC

128 n preoperative CECT is associated with early disease recurrence and poor OS and may be useful for ide

129 pression was associated with advanced stage, disease recurrence and poor prognosis.

130 regional lymph nodes indicates high risk of disease recurrence and poor survival in node-negative CR

131 odes is associated with an increased risk of disease recurrence and poor survival in patients with no

132 ma specimens were associated with more rapid disease recurrence and poorer overall survival.

133 , and HER2 expression is predictive of human disease recurrence and prognosis.

134 ith a special focus on areca nut chewing, on disease recurrence and progression in patients with non-

135 thermore, we find that IPO11 status predicts disease recurrence and progression to metastasis in pati

136 igh-risk NMIBC is the prevention or delay of disease recurrence and progression.

137 but a majority will subsequently experience disease recurrence and require further surgery.

138 mote survival and expansion, thus underlying disease recurrence and resistance to conventional therap

139 nd metastatic lymph nodes as well as between disease recurrence and scars or adverse reactions after

140 ssion clinically correlated with tumor size, disease recurrence and survival rate.

141 Long-term follow-up data for disease recurrence and survival was collected in six par

142 umor miR-106b expression was associated with disease recurrence and the combination of high miR-106b

143 vides the first link between protection from disease recurrence and the humoral response to Hla, a vi

144 h implications for improved understanding of disease recurrence and therapeutic response.

145 withdrawn for 16-36 months (tolerant), 2 had disease recurrence, and 3 had subclinical rejection in p

146 Outcomes of interest included survival, disease recurrence, and adverse events.

147 r underlying cause of therapy resistance and disease recurrence, and is a read-out of tumor growth.

148 included overall and disease-free survival, disease recurrence, and organ preservation.

149 Nodal burden, disease recurrence, and overall survival.

150 critical component of therapeutic response, disease recurrence, and patient survival.

151 NSCLC) and correlates with tumor metastasis, disease recurrence, and poor survival in patients with N

152 iation between lymphadenectomy and survival, disease recurrence, and surgical morbidity in women with

153 er diagnosis in relation to quality of life, disease recurrence, and survival.

154 lay a significant role in tumor progression, disease recurrence, and treatment failure.

155 lly facilitate early diagnosis of cancer and disease recurrence, and which could potentially inform o

156 er these SNPs affect the age of onset of the disease, recurrence, and survival.

157 late primary, adjuvant, and salvage therapy; disease recurrence; and survival in patients with T1/T2

158 with poor-risk characteristics such as early disease recurrence are candidates for aggressive salvage

159 arcinomas (HNSCC), yet treatment failure and disease recurrence are common.

160 Local and distant disease recurrence are frequently observed following pan

161 ion between specific immunologic markers and disease recurrence are needed to ultimately develop targ

162 the possibility that the drug resistance and disease recurrence associated with imatinib treatment of

163 k groups, and to predict their risk of early disease recurrence at diagnosis.

164 ial, received some trial therapy, and had no disease recurrence at the end of a symptom assessment pe

165 ter surgery, but was higher in patients with disease recurrence (based on endoscopic analysis; Rutgee

166 enal transplantation point to a high risk of disease recurrence (both DDD and C3GN) in allograft reci

167 th increased malignancy, poor prognosis, and disease recurrence, but the underlying causes of PMT are

168 g patients in PREVENT1, 53%-63% did not have disease recurrence, compared with 65% of those given pla

169 n PREVENT2, 59%-69% of patients did not have disease recurrence, compared with 68% of those given pla

170 of gastrointestinal continuity and free from disease recurrence completed the validated LARS question

171 The primary outcome was disease recurrence, defined as CIN grade 2 or higher on

172 omosome 8q22 that were associated with early disease recurrence despite anthracycline-based adjuvant

173 cancer defined by MRI can be at high risk of disease recurrence despite standard chemoradiotherapy an

174 Disease recurrence did not correlate with graft survival

175 In contrast, patients with disease recurrence displayed mechanisms of resistance in

176 t was safely interrupted with no evidence of disease recurrence during 8-37 mo (mean, 23 mo).

177 prostate cancer, with upwards of 65% having disease recurrence even after primary treatment.

178 tient with metastatic melanoma who developed disease recurrence following an initial, unequivocal rad

179 However, KRAS*-independent disease recurrence following genetic extinction of Kras*

180 tumor antigen escape mechanisms that lead to disease recurrence following many CAR T-cell therapies.

181 ients at high risk of lymphoma relapse after disease recurrence following prior autologous transplant

182 Excellent long-term disease recurrence-free survival can be achieved in sele

183 ith unresectable ICCA demonstrated promising disease recurrence-free survival.

184 still associated with postoperative risks of disease recurrence, graft failure and other complication

185 recurrent disease, ACR did not develop once disease recurrence had been seen on transbronchial biops

186 utcome including quality of life and risk of disease recurrence has yet to be fully defined.

187 d BC patients, development of resistance and disease recurrence have been the major clinical problems

188 s the risk of death due to causes other than disease recurrence (hazard ratio, 1.25; 95% CI, 1.00 to

189 tics that are associated with a high rate of disease recurrence, highlighting the need for novel trea

190 AL may be a risk factor for disease recurrence, however available studies have been

191 in HCV patients with first graft loss due to disease recurrence (HR: 0.31; P = .002, HR 0.32; P = .00

192 reatment, patients were classified as having disease recurrence if cultures grew MDR-TB or they re-in

193 followed by immunosuppression withdrawal on disease recurrence in 10 children and 20 adults with MCD

194 ogression and were independent predictors of disease recurrence in a cohort of 141 patients with AJCC

195 actors for disease-free survival and time to disease recurrence in a cohort of patients with axillary

196 in modification impacted on colonization and disease recurrence in a murine model of infection, showi

197 erexpression is a novel molecular marker for disease recurrence in breast cancer patients and may ser

198 re, shape, and tumor architecture to predict disease recurrence in early stage NSCLC from digitized H

199 s, as well as with metastatic competence and disease recurrence in multiple clinical cohorts.

200 event and treat acquired chemoresistance and disease recurrence in OC and enhance the efficacy of sta

201 o characterize the patterns and treatment of disease recurrence in patients achieving a pathological

202 can be used only as a prognostic factor for disease recurrence in patients in remission after medica

203 KL inhibition might delay bone metastasis or disease recurrence in patients with early-stage breast c

204 illance has high PPV and NPV for identifying disease recurrence in patients with HPV-associated oroph

205 veloped nomogram was demonstrated to predict disease recurrence in patients with LMS which may allow

206 The median time-to-disease recurrence in patients with low MYO1A was 1 y, c

207 riant allele were highly associated with the disease recurrence in patients with Tis, Ta, and T1 tumo

208 cinoma (HCC), up to 70% of patients may have disease recurrence in the liver at 5 years.

209 trogen receptor (ER) alpha signaling prevent disease recurrence in the majority of patients with horm

210 In particular, how disease recurrence in the renal allograft defines graft

211 vity is highly predictive of post-transplant disease recurrence in this pediatric patient population.

212 ectomy does not improve survival or decrease disease recurrence in women with early-stage, low-grade

213 assignment to the date of first evidence of disease recurrence, including biochemical failure, local

214 The hazard ratios for disease recurrence increased incrementally based on the

215 nk4a expression was strongly associated with disease recurrence, independent of standard histopatholo

216 Two of these patients had systemic disease recurrence involving the primary malignant site.

217 Finally, guidance on treatment of disease recurrence is also lacking and there is signific

218 is with high risk for asthma comorbidity and disease recurrence is characterized by type 2 inflammato

219 pairment and creates an environment in which disease recurrence is likely.

220 The risk of disease recurrence is minimized and survival often prolo

221 Disease recurrence is not an insignificant event because

222 However, disease recurrence is still observed in these patients.

223 e cell surface protein CD 138 increases with disease recurrence, is not elevated in GORD or healthy c

224 vertheless, mortality of high-risk patients, disease recurrence, lack of robustly tested salvage stra

225 ve/HER2-negative BC, with the early spike in disease recurrence markedly decreased.

226 Identification of protein markers linked to disease recurrence may yield insights into tumor biology

227 cer stem cells (CSC) have been implicated in disease recurrence, metastasis, and therapeutic resistan

228 neal, or fallopian tube carcinoma with first disease recurrence more than 6 months after first-line p

229 SC debulking surgery (n = 14) or patients at disease recurrence (n = 16).

230 ring a mean observation period of 21 months, disease recurrence occurred in 140 patients (57.9%).

231 Disease recurrence occurred in 171 patients (7.1%) in th

232 Conclusion: The present data show that disease recurrence occurs, usually after a long delay, i

233 en every 3 months for up to 3 years or until disease recurrence or an unacceptable level of toxic eff

234 l, defined as the time from randomisation to disease recurrence or death from any cause.

235 onal year of follow-up, the hazard ratio for disease recurrence or death in the capecitabine group wa

236 Disease recurrence or death occurred in 377 patients in

237 f 3.2 years, 69 patients (22%) experienced a disease recurrence or death.

238 median of 24 months (range, 2-63 months) for disease recurrence or death.

239 may serve as a nidus for recolonization and disease recurrence or for the development of furcation c

240 Markers can report on the risk of disease recurrence or metastasis, or treatment responsiv

241 therapy plus trastuzumab with no evidence of disease recurrence or metastatic disease at study entry.

242 nt was given continuously for 1 year, unless disease recurrence or new breast cancer, intolerable adv

243 tases are an important prognostic factor for disease recurrence or survival among patients with breas

244 fied into two groups: those at high risk for disease recurrence or the need for immunosuppressive tre

245 f 6.3 years, there were 165 events involving disease recurrence or the occurrence of contralateral br

246 CI; 89 to 93) with placebo (hazard ratio for disease recurrence or the occurrence of contralateral br

247 (n = 505) every 3 weeks for 1 year or until disease recurrence or unacceptable toxicity.

248 14 cycles of adjuvant T-DM1, unless there is disease recurrence or unmanageable toxicity.

249 eriologically confirmed treatment failure or disease recurrence, or death (all-cause), from randomisa

250 eriologically confirmed treatment failure or disease recurrence, or death, by enhancing early S aureu

251 ved placebo experienced treatment failure or disease recurrence, or died (absolute risk difference -1

252 lp categorize patients into those at risk of disease, recurrence, or treatment failure.

253 FDG-PET/CT was utilized for surveillance of disease recurrence outside the regional field of treatme

254 as a result of acute rejection (P < .001) or disease recurrence (P = .003), but survival was similar

255 tDNA during chemotherapy was associated with disease recurrence (P = .023), whereas pathologic downst

256 nce of mutDNA detection during NAC predicted disease recurrence (p = 0.003), emphasising its potentia

257 quately the relationship between subtype and disease recurrence, particularly when there is a substan

258 ormance for detecting LNM preoperatively and disease recurrence postoperatively in endometrial cancer

259 s post-random assignment, 40% had documented disease recurrence prior to death.

260 val in the BK group over acute rejection and disease recurrence remained after adjusting for potentia

261 Disease recurrence remains the main cause of treatment f

262 Because disease recurrence remains the major cause of treatment

263 tment is liver transplantation, and risk for disease recurrence remains.

264 chieved a pCR were less likely to experience disease recurrence (RFS, 86%) than those who did not ach

265 provide more accurate information to assess disease recurrence risk and BC-related death.

266 .7% in the tamoxifen group (hazard ratio for disease recurrence, second invasive cancer, or death, 0.

267 -ovarian suppression group (hazard ratio for disease recurrence, second invasive cancer, or death, 0.

268 HCT) is usually performed for graft failure, disease recurrence, secondary malignancy, and, as planne

269 eocolonoscopy for early detection of Crohn's disease recurrence should be part of any postoperative m

270 n of the mutations with patient survival and disease recurrence, subject to modification by a common

271 -23 signaling serum cytokines increased with disease recurrence, supporting the role of IL-23 in expa

272 odel was most sensitive to assumptions about disease recurrence, survival, and the health utility red

273 was lower (31 vs 83 months, P = 0.001), with disease recurrence that was more frequent (50.8% vs 32.7

274 ting that TAMs contribute to prostate cancer disease recurrence through paracrine signaling processes

275 RB-pathway biology that are associated with disease recurrence through the epithelial or stromal com

276 Here, we used a murine model of C. difficile disease recurrence to demonstrate that an initial infect

277 ur aim was to develop a prognostic score for disease recurrence to guide individually tailored survei

278 on, 2-weeks-off schedule for 1 year or until disease recurrence, unacceptable toxicity, or consent wi

279 en every 12 weeks until 1 year of treatment, disease recurrence, unacceptable toxicity, or withdrawal

280 01; HR for LN SUV(max), 1.32, P = 0.004) and disease recurrence (univariate analyses: HR for PT SUV(m

281 stasis to distant organ sites and more rapid disease recurrence upon removal of the primary tumor.

282 however, harbor residual leukemia cells, and disease recurrence usually occurs when imatinib is disco

283 Median survival after first disease recurrence was 27.7 months with thalidomide-pred

284 Early disease recurrence was associated with a markedly increa

285 In eight patients (seven female), disease recurrence was diagnosed by abnormal radiologica

286 Disease recurrence was diagnosed by biopsy (protocol or

287 Disease recurrence was highly suspected in 4 (7%) recipi

288 ng of tissues from patients with and without disease recurrence was performed for Ki-67 and the macro

289 Renal disease recurrence was scored using the histopathologica

290 osed cells of origin for prostate cancer and disease recurrence, we looked further into this amplific

291 Hazard ratios (HRs) for disease recurrence were generated using Cox proportional

292 A total of 361 instances (83%) of disease recurrence were observed after a median follow-u

293 we demonstrated that vancomycin only delayed disease recurrence, whereas neutralizing polysera agains

294 remission than in samples from patients with disease recurrence, which indicates that SET9 acts as a

295 ft injury, posttransplant complications, and disease recurrence, while highlighting potential areas f

296 It predicts which patients will have disease recurrence with greater accuracy than CRP level

297 zed studies to uncover mechanisms leading to disease recurrence within each individual patient are wa

298 disease categories except where the risks of disease recurrence within the first year are low, but wi

299 However, 33% of these patients had disease recurrence within the next 2 years.

300 m (ie, cured), and those who will experience disease recurrence within their lifetime (ie, susceptibl